Emerzene | Engineering the Future of Pain Relief

Engineering the Future of Pain Relief

We have harnessed the complexity of nature and genomics to develop A morphine-free starting material for the next generation of pain medicines.

Changing the Landscape of Opioid Pain Management

Pain relief is a chemistry problem. We grow the chemistry it starts from

OUR SCIENCE

Emerzene Inc is a biotechnology company on a mission to solve one of the biggest challenges with pain killers – synthetic addiction. We are the first company to use advanced gene editing techniques, enhanced CRISPR technology and sustainable agronomic practices for non-addictive poppy breeding.

Our genome-editing work is carried out under a licence from Sigma-Aldrich covering research use, with an option to convert to a commercial licence.

What our thebaine becomes

Thebaine is the starting material for oxycodone, hydrocodone and oxymorphone and for naloxone, naltrexone, nalbuphine and buprenorphine, the medicines used to reverse overdose and treat dependence. Every one of them begins with the alkaloid we grow.

A New Revolution in Pain Relief

As a vertically integrated biotechnology company, Emerzene applies research experience in agriculture and genomics to poppy cultivation.

Employing precision extraction of active pharmaceutical ingredients (API) as a production core to develop new treatments, We hold a licence to apply genome editing to a perennial poppy - so far as we are aware, the only active programme of its kind.

INNOVATION

Emerzene Therapeutics Inc facility in Liechtenstein

Plant Based. Organic. Sustainable.

We leverage synergies of plant genetics and biotechnology with sustainable agricultural production to make the critical advances necessary for medicine, human health and the environment.

Years of agronomy research, field experience and patented sustainable farming practices improve the resilience and long-term health of the soil--ultimately leading to higher yields and crop quality.

Licenses /
Patents

Licence No. 1132, Agriculture Victoria — held continuously since 2015, renewed to July 2028.

A Never-Ending Promise to Innovation

Our development began with a vision to tackle one of the biggest struggles of pain medications – chemical addiction. Thanks to our commitment to innovation, we developed exclusive methods to extract and purify our own perennial poppies.

With complete control of our own supply chain, we utilize a novel, water-based extraction process that does not require toxic solvents. Our extraction is water-based rather than solvent-based. Cost comparisons will follow first harvest.

How We Do It

By employing gene editing technology and controlling the enzymatic process during alkaloid formation, we have developed a non-addictive pain medication.

VIEW PIPELINE

How We Do It

By employing gene editing technology and controlling the enzymatic process during alkaloid formation, we have developed a non-addictive pain medication.

VIEW PIPELINE

Science

Emerzene is the first company to use advanced genetics and CRISPR technology for poppy breeding.

Manufacturing

To ensure premium quality extraction, we control and direct our own processes at our partnering facilities in Europe.

Our Values

We are passionate about the sustainable cultivation, innovative extraction processes, and management of a new species of poppy that will transform opioid pain management.

Our mission is to make a difference in the lives of patients and help end the opioid epidemic by supplying a line of effective pain medication without addiction risk.

ABOUT US

Our mission is to make a difference in the lives of patients and help end the opioid epidemic by supplying a line of effective pain medication without addiction risk.

ABOUT US

We are actively looking to partner with pharmaceutical companies for our R&D trials to propel the next generation of medicinal advances.